{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:51:05Z","timestamp":1794361865453,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Financial Disclosures The NSABP B-31 Trial was supported by NCI grants: U10CA180868, -180822, UG1-189867"],"award-info":[{"award-number":["Financial Disclosures The NSABP B-31 Trial was supported by NCI grants: U10CA180868, -180822, UG1-189867"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24-196067."],"award-info":[{"award-number":["U24-196067."]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10549-019-05453-z","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T09:04:00Z","timestamp":1570784640000},"page":"161-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["A pooled analysis of the cardiac events in the trastuzumab adjuvant trials"],"prefix":"10.1007","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Ponde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Procter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena S.","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Ballman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro Moreno","family":"Aspitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Zardavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"5453_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41571-018-0089-9","volume":"16","author":"NF Pond\u00e9","year":"2019","unstructured":"Pond\u00e9 NF, Zardavas D, Piccart M (2019) Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol 16:27\u201344. \nhttps:\/\/doi.org\/10.1038\/s41571-018-0089-9","journal-title":"Nat Rev Clin Oncol"},{"key":"5453_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. \nhttps:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"5453_CR3","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744\u20133752. \nhttps:\/\/doi.org\/10.1200\/JCO.2014.55.5730","journal-title":"J Clin Oncol"},{"key":"5453_CR4","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8\u00a0years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 32:2159\u20132165. \nhttps:\/\/doi.org\/10.1200\/JCO.2013.53.9288","journal-title":"J Clin Oncol"},{"key":"5453_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","volume":"34","author":"PP Advani","year":"2016","unstructured":"Advani PP, Ballman KV, Dockter TJ et al (2016) Long-term cardiac safety analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 34:581\u2013587. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.61.8413","journal-title":"J Clin Oncol"},{"key":"5453_CR6","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EH Romond","year":"2012","unstructured":"Romond EH, Jeong J-H, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792\u20133799. \nhttps:\/\/doi.org\/10.1200\/JCO.2011.40.0010","journal-title":"J Clin Oncol"},{"key":"5453_CR7","doi-asserted-by":"publisher","first-page":"e000073","DOI":"10.1136\/esmoopen-2016-000073","volume":"1","author":"NF Pond\u00e9","year":"2016","unstructured":"Pond\u00e9 NF, Lambertini M, de Azambuja E (2016) Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 1:e000073. \nhttps:\/\/doi.org\/10.1136\/esmoopen-2016-000073","journal-title":"ESMO Open"},{"key":"5453_CR8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. \nhttps:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"key":"5453_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","volume":"382","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2\u00a0years versus 1\u00a0year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382:1021\u20131028. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(13)61094-6","journal-title":"Lancet"},{"key":"5453_CR10","doi-asserted-by":"publisher","first-page":"12268","DOI":"10.3390\/ijms131012268","volume":"13","author":"A-S Hervent","year":"2012","unstructured":"Hervent A-S, De Keulenaer GW (2012) Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci 13:12268\u201312286. \nhttps:\/\/doi.org\/10.3390\/ijms131012268","journal-title":"Int J Mol Sci"},{"key":"5453_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao Y-Y, Fan L et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459\u2013465. \nhttps:\/\/doi.org\/10.1038\/nm0502-459","journal-title":"Nat Med"},{"key":"5453_CR12","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","volume":"44","author":"LP Grazette","year":"2004","unstructured":"Grazette LP, Boecker W, Matsui T et al (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44:2231\u20132238. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2004.08.066","journal-title":"J Am Coll Cardiol"},{"key":"5453_CR13","doi-asserted-by":"publisher","first-page":"e79543","DOI":"10.1371\/journal.pone.0079543","volume":"8","author":"MK ElZarrad","year":"2013","unstructured":"ElZarrad MK, Mukhopadhyay P, Mohan N et al (2013) Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS ONE 8:e79543. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0079543","journal-title":"PLoS ONE"},{"key":"5453_CR14","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900\u20132902. \nhttps:\/\/doi.org\/10.1200\/JCO.2005.05.827","journal-title":"J Clin Oncol"},{"key":"5453_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12:547\u2013558. \nhttps:\/\/doi.org\/10.1038\/nrcardio.2015.65","journal-title":"Nat Rev Cardiol"},{"key":"5453_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"D Zardavas","year":"2017","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ et al (2017) Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage Human Epidermal Growth Factor Receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol 35:878\u2013884. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.65.7916","journal-title":"J Clin Oncol"},{"key":"5453_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-017-4628-3","volume":"168","author":"N Ponde","year":"2018","unstructured":"Ponde N, Bradbury I, Lambertini M et al (2018) Cardiac biomarkers for early detection and prediction of trastuzumab and\/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat 168:631\u2013638. \nhttps:\/\/doi.org\/10.1007\/s10549-017-4628-3","journal-title":"Breast Cancer Res Treat"},{"key":"5453_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2017) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19:9\u201342. \nhttps:\/\/doi.org\/10.1002\/ejhf.654","journal-title":"Eur J Heart Fail"},{"key":"5453_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30650-6","author":"HM Earl","year":"2019","unstructured":"Earl HM, Hiller L, Vallier A-L et al (2019) 6 versus 12\u00a0months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(19)30650-6","journal-title":"Lancet"},{"key":"5453_CR20","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","volume":"393","author":"X Pivot","year":"2019","unstructured":"Pivot X, Romieu G, Debled M et al (2019) 6\u00a0months versus 12\u00a0months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 393:2591\u20132598. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(19)30653-1","journal-title":"Lancet"},{"key":"5453_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122\u2013131. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1703643","journal-title":"N Engl J Med"},{"key":"5453_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","volume":"11","author":"ML Henry","year":"2018","unstructured":"Henry ML, Niu J, Zhang N et al (2018) Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging 11:1084\u20131093. \nhttps:\/\/doi.org\/10.1016\/j.jcmg.2018.06.005","journal-title":"JACC Cardiovasc Imaging"},{"key":"5453_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283. \nhttps:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"key":"5453_CR24","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/JCO.19.00066","volume":"37","author":"SM Tolaney","year":"2019","unstructured":"Tolaney SM, Guo H, Pernas S et al (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2\u2013positive breast cancer. J Clin Oncol 37:1868\u20131875. \nhttps:\/\/doi.org\/10.1200\/JCO.19.00066","journal-title":"J Clin Oncol"},{"key":"5453_CR25","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671\u20131680. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"key":"5453_CR26","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S et al (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101\u2013Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870\u2013877. \nhttps:\/\/doi.org\/10.1200\/JCO.2016.68.7830","journal-title":"J Clin Oncol"},{"key":"5453_CR27","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R et al (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73:2859\u20132868. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2019.03.495","journal-title":"J Am Coll Cardiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05453-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T23:51:17Z","timestamp":1602287477000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05453-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5453"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05453-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"14 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Evandro de Azambuja has received honoraria and advisory board from Roche\/GNE and Seattle Genetics; travel grants from Roche\/GNE and GSK\/Novartis and research grants to his Institute: Roche\/GNE; AstraZeneca, GSK\/Novartis, Servier. Noam Pond\u00e9 has received honoraria from AZ and Eli Lilly and travel grants from Eli Lilly and Novartis. Marion Procter has declared that her institution received funding from Roche in respect to the HERA and APHINITY trials. Matteo Lambertini has received honoraria from Theramex and consulting fee from TEVA. Pryia Rastogi has received travel and accommodations supported by Lilly, AZ, and GNE\/Roche. Martine Piccart has been declared board Member (Scientific Board): Oncolytics, Radius; consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Periphagen, Pfizer, Roche, Seattle Genetics; research grants to her Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. Thomas Suter has declared research support from Novartis and Amgen; consultant from Pfizer and advisory Board from Alnylam. Richard D Gelber declares that his institution receives support for his salary from Roche, AstraZeneca, Merck, Novartis, Ipsen, Celgene, Pfizer, and Ferring. Dimitrios Zardavas has declared employment from BMS. Karla V. Ballman has declared consulting or Advisory Role from ARIAD; Medtronic; Takeda; Agenus; Patents, Royalties, Other Intellectual Property: Prostate cancer signature patent (Inst); Expert Testimony\u2014Janssen Oncology; Lilly. Lise Roca, Alvaro Moreno Aspitia, and Reena Cecchini have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in each of the studies (HERA, NSABP B-31 (NRG Oncology) and NCCTG N9831 (Alliance)).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}